BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32880022)

  • 21. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients.
    Shimauchi Y; Tanaka M; Kuromatsu R; Ogata R; Tateishi Y; Itano S; Ono N; Yutani S; Nagamatsu H; Matsugaki S; Yamasaki S; Tanikawa K; Sata M
    Oncol Rep; 2000; 7(2):249-56. PubMed ID: 10671666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.
    Tokushige K; Hyogo H; Nakajima T; Ono M; Kawaguchi T; Honda K; Eguchi Y; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Suzuki Y; Kogiso T; Karino Y; Munekage K; Kuromatsu R; Oeda S; Yanase M; Mori K; Ogawa Y; Seko Y; Takehara T; Itoh Y; Nakajima A; Kanemasa K; Nishino K; Masaki N; Takahashi H; Seike M; Torimura T; Saibara T; Toyota J; Chayama K; Hashimoto E
    J Gastroenterol; 2016 Jun; 51(6):586-96. PubMed ID: 26456168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
    Wong RJ; Ahmed A; Gish RG
    Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical usefulness of des-gamma-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma.
    Fujiyama S; Izuno K; Gohshi K; Shibata J; Sato T
    Dig Dis Sci; 1991 Dec; 36(12):1787-92. PubMed ID: 1721019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
    Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
    Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
    Sassa T; Kumada T; Nakano S; Uematsu T
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
    Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
    Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
    Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
    J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.
    Sterling RK; Wright EC; Morgan TR; Seeff LB; Hoefs JC; Di Bisceglie AM; Dienstag JL; Lok AS
    Am J Gastroenterol; 2012 Jan; 107(1):64-74. PubMed ID: 21931376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic value of the assay of des-gamma-carboxy prothrombin in the detection of small hepatocellular carcinoma.
    Chan CY; Lee SD; Wu JC; Lin HC; Huang YS; Lo GH; Lee FY; Tsai YT; Lo KJ
    J Hepatol; 1991 Jul; 13(1):21-4. PubMed ID: 1717542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
    Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
    Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.